Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
May 14, 2024 10:30 ET
|
Disc Medicine Inc
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a...
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
May 14, 2024 10:05 ET
|
Affimed N.V.
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated...
Trust Stamp Provides a Business Report and Financial Results for the Three Months Ended March 31, 2024
May 14, 2024 10:00 ET
|
Trust Stamp
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company™ providing AI-powered trust and identity services used globally across multiple sectors,...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
May 14, 2024 10:00 ET
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
May 14, 2024 10:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 14, 2024 10:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral...
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
May 14, 2024 10:00 ET
|
Nurix Therapeutics, Inc.
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with...
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
May 14, 2024 10:00 ET
|
Agios Pharmaceuticals, Inc.
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024 10:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
May 14, 2024 10:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress